GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » 180 Life Sciences Corp (NAS:ATNF) » Definitions » 5-Year RORE %

180 Life Sciences (180 Life Sciences) 5-Year RORE % : -45.65% (As of Mar. 2024)


View and export this data going back to 2017. Start your Free Trial

What is 180 Life Sciences 5-Year RORE %?

Return on Retained Earnings (RORE) is an indicator of a company's growth potential, it shows how much a company earns by reinvesting its retained earnings, i.e. profits after dividend payments. 180 Life Sciences's 5-Year RORE % for the quarter that ended in Mar. 2024 was -45.65%.

The industry rank for 180 Life Sciences's 5-Year RORE % or its related term are showing as below:

ATNF's 5-Year RORE % is ranked worse than
87.79% of 1081 companies
in the Biotechnology industry
Industry Median: -6.81 vs ATNF: -45.65

180 Life Sciences 5-Year RORE % Historical Data

The historical data trend for 180 Life Sciences's 5-Year RORE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

180 Life Sciences 5-Year RORE % Chart

180 Life Sciences Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23
5-Year RORE %
- - - - -

180 Life Sciences Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
5-Year RORE % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -45.65

Competitive Comparison of 180 Life Sciences's 5-Year RORE %

For the Biotechnology subindustry, 180 Life Sciences's 5-Year RORE %, along with its competitors' market caps and 5-Year RORE % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


180 Life Sciences's 5-Year RORE % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, 180 Life Sciences's 5-Year RORE % distribution charts can be found below:

* The bar in red indicates where 180 Life Sciences's 5-Year RORE % falls into.



180 Life Sciences 5-Year RORE % Calculation

180 Life Sciences's 5-Year RORE % for the quarter that ended in Mar. 2024 is calculated as:

5-Year RORE %=( Most Recent EPS (Diluted)- First Period EPS (Diluted) )/( Cumulative EPS (Diluted) for 5-year -Cumulative Dividends per Share for 5-year )
=( -41.785--939.574 )/( -1966.489-0 )
=897.789/-1966.489
=-45.65 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of 5-Year RORE %, the most recent and first period EPS (Diluted) is the trailing twelve months (TTM) data ended in Mar. 2024 and 5-year before.


180 Life Sciences  (NAS:ATNF) 5-Year RORE % Explanation

Return on Retained Earnings (RORE) is important to investors because it reveals a company's efficiency and growth potential. A higher RORE indicates a higher return. A high RORE indicates that the company should reinvest profits into the business. A lower RORE suggests that the company should distribute profits to shareholders by paying out dividends, since those dollars aren't generating much additional growth for the company.

There are a several different ways to arrive at the Return on Retained Earnings. The simplest way to calculate it is by using published information on Earnings per Share (EPS) and Dividend per Share (DPS) over a selected period. Here, 5-year period is chosen.

Be Aware

Please keep in mind that the RORE is relative to the nature of the business and its competitors. If another company in the same sector is producing a lower return on retained earnings, it doesn’t necessarily mean it’s a bad investment. It may just suggest the company is older and no longer in a high growth stage. At such a stage in the business cycle, it would be expected to see a lower RORE and higher dividend payout.


180 Life Sciences 5-Year RORE % Related Terms

Thank you for viewing the detailed overview of 180 Life Sciences's 5-Year RORE % provided by GuruFocus.com. Please click on the following links to see related term pages.


180 Life Sciences (180 Life Sciences) Business Description

Traded in Other Exchanges
N/A
Address
3000 El Camino Real, Bldg. 4, Suite 200, Palo Alto, CA, USA, 94306
180 Life Sciences Corp is a clinical-stage biotechnology company. It is focused on the development of novel drugs that fulfill unmet needs in inflammatory diseases, fibrosis and pain by leveraging the combined expertise of luminaries in therapeutics.
Executives
James N. Woody director, officer: Chief Executive Officer C/O ONCOMED PHARMACEUTICALS, INC., 800 CHESAPEAKE DRIVE, REDWOOD CITY CA 94063
Marc Feldmann director 5 DURHAM TERRACE, LONDON X0 W25PB
Lawrence Steinman director 10555 SCIENCE CENTER DRIVE, SAN DIEGO CA 92121
Mcgovern Jr. Donald A. director C/O CARS.COM, 300 S. RIVERSIDE PLAZA, SUITE 1000, CHICAGO IL 60606
Quan Anh Vu officer: COO / Chief Business Officer 22616 ERWIN STREET, WOODLAND HILLS CA 91367
Ozan Pamir officer: Interim CFO 2443 FILLMORE ST #380-17649, SAN FRANCISCO CA 94115
Pamela G Marrone director C/O MARRONE BIO INNOVATIONS, INC., 2121 SECOND STREET, A-107, DAVIS CA 95618
Teresa Deluca director 40 BURTON HILLS BOULEVARD, SUITE 500, NASHVILLE TN 37215
Russell T Ray director 2525 DUPONT DR, IRVINE CA 92612
Knuettel Ii Francis director 205 NEWBURY ST, SUITE 204, FRAMINGHAM MA 01701
Marlene Krauss director, 10 percent owner, officer: Chief Executive Officer C/O KBL HEALTHCARE INC, 645 MADISON AVE, NEW YORK NY 10022
Lawrence Marshall Gold director 830 MENLO AVENUE, SUITE 100, MENLO PARK CA 94025
Jonathan B. Rothbard officer: Chief Scientific Officer 501 BEALE STREET, UNIT 8D, SAN FRANCISCO CA 94105
Shoshana Shendelman director C/O APPLIED THERAPEUTICS, INC., 340 MADISON AVENUE, 19TH FLOOR, NEW YORK NY 10173
Richard W Barker director 290 COMMONWEALTH AVENUE #17, BOSTON MA 02115

180 Life Sciences (180 Life Sciences) Headlines

From GuruFocus